Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 7/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175661 | 0.83 | RIPK1 (0.49) | ALDH1A1HPGDHDAC1MEN1KMT2A | |
| SCHEMBL6277706 | 0.83 | RIPK1 (0.49) | ALDH1A1HPGDHDAC1MEN1KMT2A | |
| SCHEMBL6175805 | 0.80 | ALDH1A1 (0.48) | ALDH1A1HPGDHDAC1MEN1KMT2A | |
| SCHEMBL6281552 | 0.79 | FGFR1 (0.52) | ALDH1A1HPGDMEN1KMT2ALMNA | |
| SCHEMBL6285546 | 0.76 | F10 (0.42) | ALDH1A1HPGDLMNAPOLB | |
| SCHEMBL14065328 | 0.73 | KMT2A (0.52) | HPGDMEN1KMT2ALMNATP53 | |
| SCHEMBL21642492 | 0.72 | MEN1 (0.62) | ALDH1A1HPGDHDAC1MEN1KMT2A | |
| SCHEMBL31374391 | 0.72 | NPC1 (0.56) | ALDH1A1HPGDHDAC1MEN1KMT2A | |
| SCHEMBL15774565 | 0.71 | HPGD (0.62) | ALDH1A1HPGDMEN1KMT2ALMNA | |
| SCHEMBL15991875 | 0.71 | PPARG (0.62) | ALDH1A1HPGDHDAC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | CASP1, IRAK1, STS | ALDH1A1 1294/4885HPGD 3637/4885HDAC1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.